



Corrigendum: Interferon- α 2b Treatment for COVID-19

Qiong Zhou¹, Virginia Chen², Casey P. Shannon², Xiao-Shan Wei¹, Xuan Xiang¹, Xu Wang¹, Zi-Hao Wang¹, Scott J. Tebbutt^{2,3}, Tobias R. Kollmann⁴ and Eleanor N. Fish^{5*}

¹ Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ² Prevention of Organ Failure (PROOF) Centre of Excellence & Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada, ³ Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴ Systems Vaccinology, Center for Precision Health, Telethon Kids Institute, Nedlands, WA, Australia, ⁵ Toronto General Hospital Research Institute, University Health Network & Department of Immunology, University of Toronto, Toronto, ON, Canada

OPEN ACCESS

Approved by:

Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*Correspondence:

Eleanor N. Fish
en.fish@utoronto.ca

Specialty section:

This article was submitted to
Viral Immunology,
a section of the journal
Frontiers in Immunology

Received: 08 October 2020

Accepted: 09 October 2020

Published: 27 October 2020

Citation:

Zhou Q, Chen V, Shannon CP, Wei X-S, Xiang X, Wang X, Wang Z-H, Tebbutt SJ, Kollmann TR and Fish EN (2020) Corrigendum: Interferon- α 2b Treatment for COVID-19. *Front. Immunol.* 11:615275. doi: 10.3389/fimmu.2020.615275

Keywords: interferon, COVID-19, viral shedding, IL-6, inflammation, ARDS

A Corrigendum on

Interferon- α 2b Treatment for COVID-19

by Zhou Q, Chen V, Shannon CP, Wei X-S, Xiang X, Wang X, Wang Z-H, Tebbutt SJ, Kollmann TR and Fish EN (2020). *Front. Immunol.* 11:1061. doi: 10.3389/fimmu.2020.01061

ERROR IN FIGURE/TABLE

In the original article, there was a mistake in **Table 1** as published. For 'Days from symptom onset to treatment,' the IFN+ARB and ARB values were inadvertently switched. IFN+ARB should be 8.0 [5.0,11.0] and ARB should be 17.0 [10.0, 22.0]. The corrected **Table 1** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2020 Zhou, Chen, Shannon, Wei, Xiang, Wang, Wang, Tebbutt, Kollmann and Fish. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

TABLE 1 | Demographics and clinical characteristics of patient cohort.

	IFN n = 7	IFN+ARB n = 46	ARB n = 24	p-value
Age, yrs	41.3 (27–68)	40.4 (25–80)	64.5 (37–73)	<0.001
Male (%)	0 (0.0%)	20 (43.5%)	11 (45.8%)	0.076
Female (%)	7 (100%)	26 (56.5%)	13 (54.2%)	
Comorbidities (%) ^a	14.3%	15.2%	54.2%	0.002
Initial symptoms				
Fever (%)	57.1%	58.7%	70.8%	0.632
Cough (%)	42.9%	50.0%	54.2%	0.888
Fatigue (%)	14.3%	23.9%	37.5%	0.422
Myalgia (%)	14.3%	13.0%	29.2%	0.228
Headache (%)	14.3%	6.52%	4.17%	0.590
Pharyngalgia (%)	0.00%	13.0%	8.33%	0.742
Chest pain (%)	14.3%	6.52%	20.8%	0.134
Expectoration (%)	14.3%	8.70%	20.8%	0.281
Nausea (%)	0.00%	0.00%	4.17%	0.403
Diarrhea (%)	14.3%	4.35%	20.8%	0.081
Days from symptom onset to hospital admission ^b	8.0 [5.5, 15.5]	6.5 [3.0, 10.0]	10.0 [4.5, 19.5]	0.087
Days from symptom onset to 1 st treatment ^b	8.0 [6.5, 16.00]	8.0 [5.25, 11.0]	17.0 [10.0, 22.0]	<0.001

^aHypertension, diabetes, COPD, chronic bronchitis, heart disease, cancer.

^bMedian and interquartile range [Q1, Q3] are reported.